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Abstract
Background: Recently, EpCAM has attracted major interest as a target for antibody- and vaccine-based cancer
immunotherapies. In breast cancer, the EpCAM antigen is overexpressed in 30-40% of all cases and this increased
expression correlates with poor prognosis. The use of EpCAM-specific monoclonal antibodies is a promising
treatment approach in these patients.
Methods: In order to explore molecular changes following EpCAM overexpression, we investigated changes of the
transcriptome upon EpCAM gene expression in commercially available human breast cancer cells lines Hs578T and
MDA-MB-231. To assess cell proliferation, a tetrazolium salt based assay was performed. A TCF/LEF Reporter Kit was
used to measure the transcriptional activity of the Wnt/b-catenin pathway. To evaluate the accumulation of b-
catenin in the nucleus, a subcellular fractionation assay was performed.
Results: For the first time we could show that expression profiling data of EpCAM transfected cell lines
Hs578T
EpCAM and MDA-MB-231
EpCAM indicate an association of EpCAM overexpression with the downregulation of
the Wnt signaling inhibitors SFRP1 and TCF7L2. Confirmation of increased Wnt signaling was provided by a TCF/
LEF reporter kit and by the finding of the nuclear accumulation of ß-catenin for MDA-MB-231
EpCAM but not
Hs578T
EpCAM cells. In Hs578T cells, an increase of proliferation and chemosensitivity to Docetaxel was associated
with EpCAM overexpression.
Conclusions: These data show a cell type dependent modification of Wnt signaling components after EpCAM
overexpression in breast cancer cell lines, which results in marginal functional changes. Further investigations on
the interaction of EpCAM with SFRP1 and TCF7L2 and on additional factors, which may be causal for changes
upon EpCAM overexpression, will help to characterize unique molecular properties of EpCAM-positive breast cancer
cells.
Background
EpCAM is frequently overexpressed in human invasive
breast cancer [1]. We reported EpCAM overexpression
to be an independent prognostic marker for poor over-
all survival in node-positive breast cancer [2,3]. An
independent group confirmed this finding in node-nega-
tive patients too [4]. Moreover, the magnitude of
EpCAM antigen expression semiquantitatively assessed
by immunohistochemistry showed a dose-dependent
relationship with survival. In this retrospective analysis
the patient subgroup with breast carcinomas
overexpressing both EpCAM and Her-2/neu had the
worst prognosis [5]. Targeting EpCAM with a huma-
nized monoclonal antibody (Adecatumumab) in a ran-
domized multi-centre phase II trial for the treatment of
metastatic breast cancer yielded an expression- and
dose-dependent reduction in formation of new meta-
static lesions [6]. Recently, a trifunctional anti-EpCAM
antibody (Catumaxomab) has received approval by the
European Commission for the treatment of patients
with EpCAM positive tumours [7].
EpCAM has initially been identified as a cell adhesion
molecule located within intercellular adherens junctions,
where it modulates cadherin-mediated cell adhesion and
promotes epithelial cell migration and proliferation.
EpCAM expression is not only involved in epithelium
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organ development and tissue repair but also contri-
butes to epithelial cell transformation [8,9]. Regarding
EpCAM target genes, overexpression of EpCAM was
found to be associated with enhanced transcription and
translation of the proto-oncogene c-myc and the cell
cycle proteins cyclin A and E in human epithelial 293
cells as well as in murine NIH3T3 fibroblasts [10].
Furthermore, proteome analysis revealed the epidermal
fatty acid binding protein E-FABP, a major target of c-
myc, to be upregulated upon EpCAM expression in
HEK293 cells. Enhanced E-FABP expression correlated
with EpCAM expression levels in squamous cell carci-
noma lines and in primary head and neck carcinomas
[11]. Very recently, the proteolytic shedding of the intra-
cellular domain of EpCAM (EpICD) was shown to con-
fer a mitogenic signal, participating in a multimeric
nuclear complex together with FHL2, b-catenin and Lef-
1 for the induction of target gene transcription in FaDu
hypopharynx and HCT-8 colon carcinoma cells [12,13].
Furthermore, our group described that DNA methyla-
tion is a potential mechanism for the regulation of
EpCAM expression [14].
Knowledge on the role of EpCAM in the process of
carcinogenesis, tumour progression and metastasis
needs further elucidation. Presumably, consequences of
EpCAM overexpression and signaling may strongly
depend on the tumour type, stage and the tumour
microenvironment. This assumption is corroborated by
the simple clinical observation that the prognostic
impact of EpCAM expression depends on tumour type,
disease stage and host antitumour immunity [12,15].
Contradictory findings from various cell culture systems
support the view that EpCAM expression can modulate
cell proliferation, differentiation and migration, but the
outcome of modulation is strongly dependent on cell
type and origin [16-18].
So far little data exist on EpCAM signaling in breast
cancer. The impact of EpCAM expression in human
breast cancer cell lines was investigated in loss-of-func-
tion studies by silencing EpCAM expression in EpCAM-
positive breast cancer cell lines, which resulted in a
decrease in cell proliferation, migration and invasiveness,
with a concurrent increase of the detergent-insoluble
protein fractions of E-cadherin and a-a n db-catenin.
Importantly, those observations could be confirmed only
partially with the weakly EpCAM-positive non tumouri-
genic breast cancer cell line MCF-10A [17]. Since
EpCAM signaling and function has been studied primar-
ily in EpCAM-positive breast cancer cell lines with
siRNA-based knockdown, we aimed to generate overex-
pression breast cancer cell lines and characterize these
cell line models by analysing migration, proliferation
and transcriptional changes.
Methods
Cell lines and plasmids
All cell lines were obtained from American Type Cul-
ture Collection. Hs578T, MDA-MB-231 and MCF-7 cell
lines were grown in phenol red free MEM medium
(PAA) supplemented with 5 mM glutamine (Gibco) and
10% fetal bovine serum (FBS superior, Biochrom) at
37°C under 5% CO
2. SKBr-3 cells were cultivated in
McCOYs (Gibco) substituted with 5 mM glutamine and
10% FBS. A mixture of proteolytic and collagenolytic
enzymes (Accutase, PAA) was used for detachment of
the adherent cells for passaging. All cell lines were culti-
vated at maximum to passage 25 (3 months) and the
absence of mycoplams contamination was controlled by
using Venorgem PCR based detection kit (Minerva
Biolabs).
EpCAM coding sequence was cloned into the pIRE-
Spuro3 vector (Clontech) to get a high CMV promoter
driven protein expression. Stable EpCAM expressing cell
lines as well as respective empty vector control lines
were established by transfections using Nucleofector Kit
V (Amaxa) followed by puromycine selection.
Western blotting
50 μg of protein heated in Laemmli sample buffer was
loaded per lane, resolved by a 4-20% SDS-PAGE (Criter-
ion, Biorad) and transferred onto a nitrocellulose mem-
brane (0.2 μm pore size, Schleicher & Schuell) for
western blotting at 150 mA for 2 hours. To control pro-
tein transfer, the membrane was incubated 5 min in a
Ponceau S staining solution until protein lanes were
visible. After washing steps with TBS-T, the membrane
was blocked 1 hour with 10% non-fat dry milk diluted
in TBS-T. Primary antibodies were incubated in 1%
non-fat dry milk diluted in TBS-T at 4°C over night.
Secondary HRP-labelled antibodies were incubated for 1
hour at room temperature. After incubation with ECL
Western blot detection reagent (Amersham), the detec-
tion followed by exposing the membrane to an X-ray
film (Agfa).
Antibodies used for Western analysis were: C-10
(mouse monoclonal against amino acids 24-93 of
human EpCAM, Santa Cruz Biotechnology), E144 (rab-
bit monoclonal antibody against the C-terminus of
human EpCAM, Epitomics), b-Catenin (BD Biosciences),
pan-actin (Ab-5 Clone, ACTN05, Neomarkers), GAPDH
6C5 (Santa Cruz Biotechnology), lamin A/C (2032, Cell
Signalling) and anti-TCF7L2 (clone 6H5-3, Upstate
Biotechnology).
Immunofluorescence
Cells were plated at different densities on non-coated or
gelatine-coated glass coverslips and prepared for immuno-
fluorescence after additional 48 h hours. Cells were
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Triton X-100 in PBS for 5 minutes and fixed in 2% PFA in
PBS for 30 minutes. Primary antibodies (NCL-ESA, 1:100,
mouse monoclonal anti-EpCAM, clone VU1D9, Novocas-
tra and C-10, 1:50, Santa Cruz Biotechnology) were used
with the respective Alexa 488 labelled secondary serum
(Molecular probes). F-actin was visualized using Alexa 568
Phallodin (Molecular probes).
Confocal microscopy was performed with a microlens-
enhanced Nipkow disk-based confocal system Ultra-
VIEW RS (Perkin Elmer, Wellesey MA, USA) mounted
on an Olympus IX-70 inversem i c r o s c o p e( O l y m p u s ,
Nagano, Japan). Images were aquired using the Ultra-
VIEW RS software (Perkin Elmer).
Subcellular fractionation
To generate nuclear and cytoplasmic lysates NE-PER
fractionation kit was used (Pierce 78833). A stepwise
lysis of cells generated both functional cytoplasmic and
nuclear protein extracts. Protocol was performed
according manufacturer’s instructions.
Cell counting kit
Proliferation and cell viability analysis was performed by
using Cell Counting Kit-8 (CCK-8, Dojindo Molecular
Technology) according manufacturer’s instructions.
Cells plated in 96-well plates (5 replica wells for each
cell line). At intervals of 24 hours, CCK-8 solution was
added directly to the cells (dilution 1:10) and the absor-
bance at 450 nm was measured after 4 hours of incuba-
tion in a microplate reader (Biorad). Cell numbers of
non transfected cells have been quantified once in paral-
lel by thymidine incorporation assay. Different clones of
transfected cell lines were analysed.
Chemotherapeutic sensitivity testing
Cells were seeded at equal amounts (1000 cells for
MDA-MB-231, 5000 cells for Hs578T) into 96 well
plates and allowed to adhere over night. Then, cells
were treated for 24 hours with different doses of Doce-
taxel (Taxotere
®, Sanofi Aventis): respectively Hs578T -
0, 0.005, 0.01, 0.1, 0.5 μg/mL; MDA-MB-231 - 0, 0.01,
0.1, 0.5, 1 μg/mL. CCK-8 solution was added to deter-
mine cell viability and proliferation. Absorbance was
measured at 450 nm after 4 hours of incubation.
Matrigel invasion assay
The FluoroBlok BioCoat™ Tumour Invasion System
(BD Biosciences) was used to assess the invasive poten-
tial of cell lines in vitro. Membranes (8 μm Fluoro-
Blok™ PET membranes coated with a uniform layer of
BD Matrigel™ matrix) were rehydrated and cells were
seeded into the upper chamber insert. To facilitate
migration and invasion a serum gradient was used. Cells
were allowed to migrate for 22 hours. To quantify
migration, cells in the lower chamber were stained with
calcein (BD), and the fluorescence was measured at
Cytofluor4000 fluorescence reader (MTX Lab Sytems).
The amout of migrated cells in the EpCAM transfected
lines was compared to the migration rates of their
respective empty vector control lines.
Wnt signal activity determination
The Cignal™ TCF/LEF Reporter Kit (SABiosciences,
MD) was used to determine Wnt signaling activity. A
construct containing a promoter with TCF binding
motifs in front of a Firefly luciferase gene was trans-
fected into the cell lines. b-catenin binding to the TCF
motif resulted in the transcription and translation of the
luciferase and in the emission of a bioluminescence
signal which was detected on a CHAMELEON multi-
technology platereader (Hidex). To normalize on trans-
fection efficiency, a CMV promoter driven Renilla
luciferase was co-transfected. The luciferase substrates
were purchased from Promega (Dual-Luciferase
® Repor-
ter (DLR) Assay, E1910) and added automatically by a
dual-injector system according to manufacturer’s
protocol.
Each cell line was transfected in triplicates with the
TCF construct (or negative/positive control construct
containing manipulated TCF binding motifs) plus the
Renilla control using SUREfect transfection reagent
(SABiosciences) and assayed after 48 hours. Biolumines-
cence signal intensity was determined after normaliza-
tion on transfection intensity according to following
formula: Relative Response Ratio = (SignalRepoter-Signal-
Negative Control)/(SignalPositive Control-SignalNegative Control)
RNA isolation and analysis
Total RNA was isolated by using TRI-reagent (Molecu-
lar Research Centre) alone or in combination with the
RNeasy MinElute Cleanup Kit (Qiagen) following the
manufacturer’s protocol. Concentration and purity of
each sample were assessed by absorbance at 260 nm
and by the 260/280 nm ratio, respectively. Phenol con-
taminations were controlled by the 260/270 nm ratio
and the concentration was adjusted [19]. The integrity
of the RNA was controlled on ethidium bromide-stained
agarose-formaldehyde gels. For the samples used for
Affimetix Chip analysis, RNA quality was determined on
an Agilent 2100 Bioanalyzer and by photometric
analysis.
Array data analysis
GC Robust Multi-array Average (GCRMA) background
adjustment, quantile normalization and median-polish
summarization on Affymetrix HGU133 plus 2.0 micro-
array probe-level data were performed using R 2.7.1 and
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tion). The log2 transformed absolute expression values
of the treatment sample (EpCAM positive line) were
subtracted from the absolute expression values of the
control sample (control line) in a gene-wise manner.
The resulting log2 transformed relative expression
values were ranked according to the level of the values.
The top 5% and lowest 5% of the probesets were
selected for further analysis. Ingenuitiy
® Pathway Analy-
sis (IPA) software (Ingenuity Systems Inc., Redwood
City, CA) was used to inter-connect GO classified cate-
gories of the obtained gene set in a context specific
manner in order to establish a regulatory network
model.
Real-time PCR
Single stranded cDNA was synthesized from 1 μgt o t a l
RNA using random primers and SuperScript II Reverse
Transcriptase (Invitrogen) according manufacturer’s
instructions. Real-time analysis was performed using 20
ng single stranded cDNA as well as specific primers and
SensiMixPlus containing SYBR
® Green (Quantace) on a
Rotor Gene 6000 cycler (Corbett Research) using follow-
ing conditions: 95°C 300 sec; 40 cycles: 95°C 10 sec,
60°C 15 sec, 72°C 10 sec (acquiring on Sybr Green). Pri-
mer specificity was checked by melting curve analysis.
For each primer pair (Table 1) the PCR amplicon length
was verified once by gel electrophoresis and the
sequence was analysed. All applications of different
cDNA input (n = 3, n = 4) were performed in replicates.
The TATA box-binding protein (TBP) was used as
endogenous control for normalization [20,21].
Relative expression ratios (R) of target genes were cal-
culated based on the normalized Ct deviation of the
EpCAM expressing cells versus the control cells accord-
ing the mathematical model described by M. Pfaffl: ratio
=( 2 ^ ΔCttarget(control-EpCAM))/(2^ΔCtTBP(control-
EpCAM)). The Ct value is defined by the cycle at which
the threshold is crossed, and ΔCt is the crossing point
difference between sample and control [22].
The relative expression software tool REST 2008 (by
M. Pfaffl and Corbett Research) was used for statistical
analysis. Two groups (controls and EpCAM-positive
cells) were compared based on their mean crossing
point deviation for significance by a randomization test.
The resulting hypothesis test value p(H1) is an indicator
of probability that the difference between sample and
control group is significant [23,24].
Results
Only few commercially available immortalized human
breast cancer cell lines lack EpCAM expression. Hs578T
and MDA-MB-231 cells were found to express none or
only very little EpCAM mRNA and protein in compari-
son to established and well characterized breast cancer
cell lines such as MCF-7 or SK-BR-3 [25].
Both Hs578T and MDA-MB-231 cells were stably
transfected with the EpCAM cDNA containing con-
struct pIRESpuro3_EpCAM. The resulting cell lines
were designated Hs578T
EpCAM and MDA-MB-
231
EpCAM; the cell lines transfected with the empty con-
trol vector pIRESpuro3 were named Hs578T
control and
MDA-MB-231
control, respectively. Parental MDA-MB-
231 cells were originally derived from a malignant
pleural effusion. MDA-MB-231 cells are highly prolifera-
tive, invasive in vitro and tumourigenic in nude mice
[26]. Hs578T cells were derived from an invasive ductal
carcinoma, show low invasive potential and are non-
tumourigenic [27,28]. Of note, both cell lines lack E-
cadherin expression (due to promoter methylation),
which is a common feature among carcinoma cell lines
with low or absent EpCAM expression.
EpCAM protein undergoes posttranslational modification
Using SDS-PAGE, EpCAM protein was detectable as a
double band in both transfected breast cancer cell lines
as well as in MCF-7 control lines under denaturing con-
ditions. After treating cell lysates with the glycosidase
PNGase F, both of these EpCAM protein bands were
shifted to a lower molecular weight but were still detect-
able as a doublet, indicating that N-linked glycosilation
is not responsible for these two different species of the
Table 1 Primer sequences used for real-time PCR
Gene GenBank Acc. Nr. sequence (5’to 3’)
TBP NM_003194 fwd TGCACAGGAGCCAAGAGTGAA
rev CACATCACAGCTCCCCACCA
EpCAM NM_002354 fwd CGCAGCTCAGGAAGAATGTG
rev TGAAGTACACTGGCATTGACG
TCF7L2 NM_030756 fwd TGCACTGTCCAGAGAAGAGC
rev GCTGCTTGTCCCTTTTCCTC
fwd TCAATGAATCAGAAACGAATCAA
rev CTCTTGGCCGCTTCTTCC
SFRP1 NM_003012 fwd GAGTTTGCACTGAGGATGAAAA
rev GCTTCTTCTTCTTGGGGACA
ITF-2 NM_001083962 fwd AGCCATTCTCTTCTGCCAAA
NM_003199 rev CAGGTTCTCATCACCCTCGT
CCND1 NM_053056 fwd GCTGCTCCTGGTGAACAAGC
NM_001758 rev TTCAATGAAATCGTGCGGG
MYC NM_002467 fwd CTACGCAGCGCCTCCCTCCACT
rev GGCGCTCCAAGACGTTGTGTGTTC
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tion modification might be of functional importance.
Localization of EpCAM determined by confocal
microscopy
Confocal microscopy analysis revealed that localiza-
tion of EpCAM antigen was strongly influenced by
cell density in monolayer cell cultures. Highly conflu-
ent monolayers showed a predominantly membranous
EpCAM staining, while single cells lacking contact
with neighbouring cells exhibited much weaker mem-
brane but stronger cytosolic staining. Cell membrane
areas at intercellular contact regions stained strongest
for EpCAM protein (Figure 2). Since physical interac-
tions of EpCAM and E-cadherin have been proposed
[9], confocal microscopy analysis demonstrated that
E-cadherin expression at the cell surface was not
necessary to recruit EpCAM to the cell membrane in
confluent Hs578T
EpCAM and MDA-MB-231
EpCAM
cells.
The results obtained by confocal microscopy and sub-
cellular fractionation in the transfected EpCAM-positive
cell lines were comparable to the endogenously
EpCAM-expressing MCF-7 and SK-BR-3 cell lines. For
this reason, Hs578T
EpCAM and MDA-MB-231
EpCAM
cells provided us with an excellent tool to investigate
EpCAM-mediated changes on cellular and molecular
levels.
Hs578T
EpCAM cells show enhanced proliferation and
chemosensitivity
EpCAM overexpression has been reported to be asso-
ciated with a strongly invasive and aggressive tumour
phenotype in breast cancer [2,3,17]. However, by using a
Matrigel™ coated Boyden chamber assay to compare
the in vitro migration/invasion properties of EpCAM-
expressing cell lines with their EpCAM-negative empty
vector counterparts, no difference in cell migration and
invasiveness could be found even by optimizing experi-
mental conditions and prolonging migration time
(Figure 3).
To assess cell proliferation, a tetrazolium salt based
assay (CCK-8) was performed. The same methodology
was used by other groups for the functional analysis of
EpCAM function in EpCAM overexpressing HEK293
cancer cells, where EpCAM positive cells exhibited
enhanced proliferative and metabolic activity compared
to cells with low or no antigen expression [10,11,29].
We additionaly compared proliferation by thymidine
incorporation with the results of the CCK-8 test, and
found the CCK-8 assay to be a reasonable alternative
to classical radioactive methods for these cell lines. In
our experiments, Hs578T
EpCAM cells showed a shor-
tened doubling time as compared to non transfected
cells and empty vector controls. This effect has been
observed 48 to 72 hours after cell seeding (Figure 4)
and was reproduced in different transfected cell clones.
Figure 1 EpCAM protein expression. (A) Western blot analysis of EpCAM in the stable transfectants and control cell lines. Observation of the
appearance of two protein species (43 and 34 kDa). Actin was used as loading control. Its molecular weight is about 45 kDa. (B) PNGase F
treatment of MCF-7 cells. To analyse if the two EpCAM protein species derive from distinct glycosilations, MCF-7 lysates were incubated with the
glycosidase PNGase F. As both protein bands shift in height, N-linked glycosilation is not responsible for the existence of two species (* =
potential degradation products).
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Page 5 of 14Figure 2 Microscopical analysis of EpCAM localization. Confocal microscopy of generated and endogeneously EpCAM overexpressing cell
lines as well as vector controls revealed an increase of EpCAM membraneous staining with cell density. Cells with a cytosolic distribution could
be observed in cultures of low confluence. Actin staining with phalloidin revealed slight changes of the actin cyctoskeleton formation upon
EpCAM expression.
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detected by comparing MDA-MB-231
EpCAM cells to
the respective empty vector control cells, suggesting
that the in vitro growth-promoting effect of the
EpCAM antigen is not universal but depends on
individual cell features. In line with these results,
Hs578T
EpCAM but not MDA-MB-231
EpCAM cells
showed enhanced chemosensitivity to Docetaxel treat-
ment compared to their empty vector counterparts
(Figure 5).
Figure 3 Migration/invasion assay. (A) Schematic presentation of an Fluoroblock BioCoat™ invasion chamber (BD) composed of a Matrigel™
coated transwell insert containing an 8 μm pore size membrane. The Matrigel matrix locks the pores of the membrane and therefore blocks
non invasive cells from migrating. Invasive cells can degrade this basement membrane reconstitution and migrate through the pores. (B) Cells
have been seeded at high density into the upper chamber. Migration was stimulated by a serum gradient. After 22 hours the amount of
migrated cells has been measured with the Cytofluor4000 fluorescence reader (MTX Lab Systems) from the bottom after cell labelling with
calcein (BD), a staining dye for vital cells only. The FluoroBlok™ membrane efficiently blocked the transmission of light into the upper chamber,
therefore the measured signal derived from migrated cells only. Although all cells migrated efficiently, no difference could be detected by
comparing Hs578T
EpCAM and MDA-MB-231
EpCAM cells with their respective empty vector control lines (set as 100%).
Figure 4 Cell proliferation assay. In a tetrazolium salt based assay, the proliferative behavior of cell lines with stable EpCAM expression in
comparison to empty vector control and untransfected cells has been measured. EpCAM transfected Hs578T cells show enhanced doubling
frequency than non-transfected cells and empty vector controls. This effect appears two days after cell seeding. No similar effect could be
detected in the stable transfected MDA-MB-231
EpCAM cell line. Absorbance was normalized to the 24 hours values.
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EpCAM and MDA-MB-231
EpCAM cells show
expression changes of Wnt pathway components
In order to investigate changes of the transcriptome on
EpCAM gene overexpression in human breast cancer
cells, global gene expression analysis using the human
genome U133 Plus 2.0 chip (Affymetrix) was performed.
Differential gene expression analysis was performed by
comparing expression levels from Hs578T
EpCAM cells
(GEO accession numbers: GSE25743, GSM632607,
GSM632608) with the respective empty vector control.
The top and lowest 5% of probe sets were used for
further analysis by Ingenuitiy
® Pathway Analysis (IPA)
software (Ingenuity Systems Inc., Redwood City, CA).
Interestingly, alterations of the Wnt signaling pathway
components were found in both EpCAM-transfected
cell lines. In more detail, we found the secreted frizzled
related protein 1 (SFRP1) - a Wnt ligand competitor
and therefore signaling inhibitor - and the HMG box
containing transcription factor 7 like 2 (TCF7L2), a
Wnt-responsive transcription factor which can also act
as repressor of signaling, to be significantly downregu-
lated after EpCAM overexpression. Additionally, the
mRNA level for the immunoglobulin transcription factor
2 (ITF-2) was diminished. Only recently, ITF-2 has been
identified as a Wnt downstream target [30]. A schematic
representation of SFRP1, TCF7L2 and ITF-2 proteins is
illustrated in Figure 6.
Changes on the mRNA level detected by expression
arrays were confirmed by real-time PCR. TATA box-
binding protein (TBP) mRNA expression was not signif-
icantly different between control and EpCAM-positive
cell lines and served as optimal housekeeping gene. To
determine the expression differences of SFRP1, TCF7L2
and ITF-2 in EpCAM positive cells we calculated nor-
malized mean expression levels (Table 2). SFRP1-specific
mRNA was consistently downregulated up to 35.8-fold
in Hs578T
EpCAM a n du pt o1 1 - f o l di nM D A - M B -
231
EpCAM cell lines in comparison to the respective
controls. TCF7L2, was downregulated in MDA-MB-
231
EpCAM cells with a 3.6-fold change while in
Hs578T
EpCAM cells the TCF7L2 mRNA level was only
marginally decreased. In line with these results, protein
levels of TCF7L2 were downregulated in MDA-MB-
231
EpCAM cells (Figure 7). ITF-2 mRNA was downregu-
lated in MDA-MB-231
EpCAM cells until the limit of
detection (>1500-fold, ΔΔCt value > 10). In Hs578T
Ep-
CAM cells, ITF-2 expression was decreased only 3.5
times.
In order to evaluate the obtained regulations in a
group-wise comparison we tested the expression differ-
ences between EpCAM positive cell lines and the
respective controls for significance with a Pair Wise
Fixed Reallocation Randomization test by using the
REST
© relative expression software tool. The perceived
differences between EpCAM expressing cells and con-
trols were of statistic significance for the downregulation
of SFRP1 in both MDA-MB-231
EpCAM and Hs578T
Ep-
CAM cell lines and for TCF7L2 and ITF-2 in MDA-MB-
231
EpCAM cells (p(H1) < 0.05).
An EpCAM-associated downregulation of inhibitory
and repressor molecule expression might contribute to
the activation or enhancement of Wnt signaling in
breast cancer and therefore further corroborate the
ongogenic potential of the EpCAM tumour antigen.
Figure 5 Docetaxel sensitivity testing. Hs578T
EpCAM and Hs578T
control cells (A) as well as MDA-MB-231
EpCAM and MDA-MB-231
control (B) cells
have been treated one day after seeding with different amounts of the chemotherapeutic Docetaxel for 24 hours. Sensitivity to the
chemotherapeutic was evaluated in % proliferation (±SEM) with 100% proliferation for untreated cells. Hs578T
EpCAM cells were more sensitive to
Docetaxel treatment as compared to their EpCAM negative counterpart Hs578T
control, whereas no difference in sensitivity could be detected in
MDA-MB-231 transfectants. Docetaxel is known to inhibit mitosis by blocking the microtubule apparatus, therefore we suggest that the
enhanced sensitivity of Hs578T
EpCAM cells can be related to their enhanced proliferation rate.
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EpCAM
cells
Fractionation analysis of cell lysates revealed the appear-
ance of EpCAM protein in the soluble cytosolic, the
nuclear and the insoluble membraneous fractions in the
transfected Hs578T
EpCAM and MDA-MB-231
EpCAM cell
lines (Figure 8). This confirmed the distribution pattern
obtained by our group and others in breast cancer-
derived as well as in mouse fibroblast cell lines [17,31].
In MDA-MB-231
control and in HS578T
EpCAM as well as
in Hs578T
control cells, similar amounts of b-catenin were
found in the cytosolic and in the nuclear protein
fraction (Figure 8). In MDA-MB-231
EpCAM cells, a
nuclear accumulation of ß-catenin was accompanied
consistently by a decrease in b-catenin levels in the
cytosol, whereas in Hs578T cells the expression of
EpCAM had no significant impact on b-catenin
distribution.
As cells were cultivated only to 70-80% density, a
majority of the EpCAM protein (detected by C-10 anti-
body) was present in the cytosol. EpCAM was addition-
ally detected with a C-terminal directed antibody
(E144). The presence of EpCAM in the nuclear fraction
suggests localization in the perinuclear compartment.
Figure 6 Schematic representation of TCF7L2, SFRP1 and ITF-2. (A) TCF7L2 can be divided in 3 major domains: the b-catenin binding
domain (CTNNB1), the DNA-binding HMG box and a C-terminal domain which is variable in many isoforms. Only the long form is able to bind
to the COOH-terminal binding protein (CtPB), the C-terminus has an important regulatory function. The presence of the CtBP motif is required
for the possible repressor function of TCF7L2. Many splicing variants (>16) have been described and each cell expresses more than one variant
[32,37]. (B) SFRP1 is a secreted protein and contains a frizzled typical cysteine rich domain (Fz-CRD) which displays the putative Wnt-ligand
binding site. The C-terminal part of the protein shows homology to netrin (NTR), an extracelluar protein involved in axonal guidance. NTR
domains are involved in protein binding and contain segments rich of positively charged residues. This region is reported to bind to heparin
[34]. (C) ITF-2 binds to DNA via its basic-helix-loop-helix (bHLH) domain and can be regulated by b-catenin. The Pitt-Hopkins syndrome (PTHS), a
rare syndromic encephalopathy, is caused by ITF-2 haploinsufficency. At least 3 isoformal sequences have been described. The two major
isoforms, ITF-2A and ITF-2B, have different N-termini resulting from alternative promoter usage [30]. (⋆ = glycosilation, p = phosphorylation.
Swissprot accession numbers Q9NQB0, Q8N474, P15884).
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Page 9 of 14Higher activity of Wnt pathway signaling in MDA-MB-
231
EpCAM cells
To further confirm these data, the Cignal™ TCF/LEF
Reporter Kit (SABiosciences, MD) was used to measure
the transcriptional activity of a b-catenin-responsive
luciferase reporter. After 48 hours of incubation lucifer-
ase activities were evaluated, normalized to the
transfection controls and the signaling intensities of
EpCAM positive cells were then compared with the
values obtained from the corresponding control cell
lines (Figure 9).
Wnt activity in Hs578T
EpCAM cells was only slightly
higher than in Hs578T
control cells (3.7% +/- 1.4%) sug-
gesting that down-regulation of the SFRP1 inhibitor
Table 2 Real-time PCR
Expression of
TBP SRFP1 TCF7L2 ITF-2
n = 3 Ct ± SD CV[%] Ct ± SD CV[%] Ct ± SD CV[%] Ct ± SD CV[%]
MDA-MB-231
control 22.11 ± 1.90 4.95 31.42 ± 2.90 9.22 19.19 ± 1.45 7.54 23.47 ± 0.43 1.82
MDA-MB-231
EpCAM 21.81 ± 0.10 0.47 34.37 ± 1.80 5.25 20.75 ± 0.27 1.33 36.26 ± 5.50 15.18
comparison EpCAM expressing versus control
Regulation Factor -11.06 -3.64 -1773.84
REST analysis
P(H1) 0.000 0.000 0.000
Result DOWN DOWN DOWN
Expression of
TBP SRFP1 TCF7L2 ITF-2
n = 4 Ct ± SD CV[%] Ct ± SD CV[%] Ct ± SD CV[%] Ct ± SD CV[%]
Hs578T
control 23.23 ± 0.72 3.09 25.35 ± 2.07 8.17 21.28 ± 0.86 4.04 22.73 ± 1.81 7.96
Hs578T
EpCAM 22.54 ± 0.18 0.81 28.50 ± 3.39 11.91 20.76 ± 0.56 2.71 23.42 ± 0.54 2.30
comparison EpCAM expressing versus control
Regulation Factor -35.82 -0.73 -3.55
REST analysis
P(H1) 0.048 0.658 0.128
Result DOWN not different to control not different to control
Quantification of differential mRNA expression of the Wnt signaling components SFRP1, TCF7L2 and ITF-2 in the stable EpCAM expressing cells in comparison to
the empty vector control lines. (SD = standard deviation, CV = coefficient of variation, REST P(H1) = hypothesis test p value, significant if < 0.05).
Figure 7 TCF7L2 protein expression. Western Blot showing lower amounts of TCF7L2 protein expression in MDA-MB-231
EpCAM cells compared
to their empty vector counterparts.
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Page 10 of 14alone is not sufficient to achieve a strong activation of
Wnt signaling. In contrast, MDA-MB-231
EpCAM cells
showed a 19.5% +/- 7.0% higher activity of Wnt pathway
signaling compared to empty vector control cells.
Discussion
Our results show the effect of constitutive EpCAM
expression in previously EpCAM antigen negative or
low expressing parental human breast cancer cell lines
Hs578T and MDA-MB-231. Of note, most other com-
mercially available human breast cancer cell lines are
characterized by a high level of EpCAM protein expres-
sion, thus low or even no EpCAM expression is a rare
occurring property. Hs578T cells are used as an example
for a low-tumourigenic EpCAM-negative cell line,
w h e r e a sM D A - M B - 2 3 1i su s e da sa ne x a m p l ef o ra
more tumourigenic one. Given that only these two
breast cancer cell lines could be used for gain-of-func-
tion studies, and the resulting phenotypes were not con-
sistent, further investigation will be needed to elucidate
a potential in vivo relevance of the presented findings.
However, the expression of EpCAM affected cancer-
related signaling molecules in both cell lines and seemed
to contribute in triggering complex biological processes,
which account for an aggressive tumoural behaviour.
In the transfected, constitutively EpCAM-expressing
human breast cancer cell lines described here, we
observed a reduced expression of Wnt signaling asso-
ciated components after EpCAM overexpression. We
found the downregulation of mRNA levels for SFRP1 in
both Hs578T
EpCAM and MDA-MB-231
EpCAM cells, and
TCF7L2 in MDA-MB-231
EpCAM only. These are two
important negative regulators of Wnt signaling [32].
The results on proliferation and Wnt signaling activa-
tion between cell lines were not consistent. As such,
Wnt signaling was activated significantly in MDA-MB-
231
EpCAM but not in Hs578T
EpCAM.I nc o n t r a s tt ot h e s e
data, proliferation and chemosensitivity was increased in
Hs578T
EpCAM but not in MDA-MB-231
EpCAM.
Canonical Wnt signaling hinges on four complexes:
the Wnt-frizzled receptor complex in the membrane,
the b-catenin destruction complex, the nuclear TCF/
LEF/b-catenin transcriptional activator complex and the
nuclear TCF/LEF transcriptional repressor complex [33].
SFRP1 acts as a repressor, it binds directly to Wnt
ligands and competes with their ability to activate the
Figure 8 Subcellular fractionation analysis. In Hs578T
EpCAM and MDA-MB-231
EpCAM cells and their respective control cell lines, b-catenin was
highly expressed in all cell lines, but only in the MDA-MB-231
EpCAM cell line a significant and reproducible accumulation of b-catenin could be
observed in the nuclear compartment, which resulted in an increased Wnt signaling activity. The mainly cytosolic protein GAPDH was used to
control the purity of the cytosolic fractionation. To show integrity of the nuclear fraction lamin a/c antibody was used. Pan-actin was used as
loading control. As cells were cultivated to 70-80% density, a majority of the EpCAM protein was present in the cytosol. Additionally to the N-
terminal directed anti-EpCAM antibody C-10, EpCAM was detected with a C-terminal directed antibody (E144). Interestingly, EpCAM could be
detected in the nuclear fraction with both antibodies.
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Page 11 of 14frizzled receptors [34]. SFRP1 siRNA treatment in the
immortalized, non-transformed human mammary
epithelial cell line MCF-10A caused a modest but repro-
ducible increase in luciferase activity in a TCF/LEF acti-
vation assay. This activity was further enhanced by
addition of Wnt-3A conditioned media [34]. As expres-
sion of SFRP1 in breast cancer counteracts Wnt signal-
ing, we proposed that its reduction leads to enhanced
Wnt signaling in breast cancer cells.
In MDA-MB-231
EpCAM cells mRNAs for both SFRP1
and TCF7L2 were down-regulated compared to the cor-
responding empty vector line and Wnt signaling was
about 20% more active. Of note, Low SFRP1 expression
in human breast cancer has been reported by several
groups independently [35,36]. Both low SFRP1 and
TCF7L2 levels have been described in a subset of breast
carcinomas derived from infiltrating ductal carcinoma
[32]. However, reduction of SFRP1 expression only, was
not sufficient to enhance Wnt signaling in Hs578T
Ep-
CAM cells compared to Hs578T
control cells. Probably, the
reduction of both SFRP1 and TCF7L2 is required to
more potently enhance Wnt signaling in breast cancer
cell lines, and a contribution of additional factors cannot
be excluded.
The transcription factor TCF7L2 belongs to the TCF/
LEF (T-cell factor/lymphoid enhancer factor) protein
family and is expressed in many isoformal variants
which can coexist in one cell. The short isoforms lack
the C-terminal protein binding sites (CtBP) which con-
vert the long variants of TCF7L2 into a repressor [37].
It is therefore conceivable that downregulation of a
repressive variant of the TCF7L2 protein in MDA-MB-
231
EpCAM cells might favour Wnt signaling mediated
through other activating TCF/LEF proteins.
Although downregulation of tumour suppressors is a
common mechanism during cancer progression, acti-
vation of Wnt signaling via the suppression of repres-
sors observed in our breast cancer cells differs from
the mechanism discovered for colon cancer, where
Wnt pathway activation occurs through loss-of-function
mutations of negative pathway components e.g. adenoma-
tous polyposis coli (APC) or gain-of-function mutations in
genes activating Wnt signaling (i.e. b-catenin) [38]. Our
findings in human breast cancer lines underscore the com-
plexity of Wnt pathway in human cancer [33].
EpCAM and b-catenin proteins were detectable in
nuclear lysates of both MDA-MB-231
EpCAM and
Hs578T
EpCAM, but the nuclear staining for EpCAM was
negative in confocal microscopy. As the antibody used
for microscopical analysis was directed against the extra-
cellular domain, a detection of the shedded cytoplasmic
fragment EpICD was not possible. Regarding the results
otained for full-length EpCAM in the fractionation
experiment, we suppose that EpCAM has a perinuclear
location and cofractionates with nuclear proteins. How-
ever, further experiments are required to establish a
relationship to the perinuclear space and the endoplas-
matic reticulum.
The activation of TCF/LEF by b-catenin is a crucial
step in the direct activation of Wnt target genes. In many
studies the expression of key target genes such as cyclin
D and c-myc is used as a read-out for Wnt signaling
activity [10,39]. Upregulation of cyclin D and c-myc has
b e e nf o u n dt ob es t r o n g l ya ssociated with breast cancer
progression [38-40]. However, although expressed at
moderate levels in parental cell lines, no significant upre-
gulation of both genes could be detected in Hs578T
Ep-
CAM and MDA-MB-231
EpCAM cells (data not shown). In
Figure 9 Wnt signaling activity assay. Upon activation of Wnt signaling a luciferase emitted bioluminescence signal is measured. A reporter
plasmid containing a constitutive active TCF/LEF motif determined the 100% activation value while a mutated motif lacking any consensus site
for b-catenin binding represented the background luminescence level. Hs578T
EpCAM cells showed only a modest activation, whereas EpCAM
overexpression in MDA-MB-231
EpCAM could activate Wnt signaling about 20% in comparison to their empty vector controls.
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Page 12 of 14line with our observation, it has been reported that in the
absence of distinct TCF7L2 variants the regulation of
common TCF/LEF target genes such as cyclin D1, c-myc,
MMP7 and c-jun is not detectable in renal cell carcinoma
and colorectal cancer cell lines [41]. As each cell type is
able to express multiple isoforms of TCF7L2 the combi-
nation of long repressory and short activating variants of
TCF7L2 adds even more complexity to the signaling
events, thus target gene expression can be affected in
many different ways [37,42]. Furthermore, the type of
trigger and feedback loops within the Wnt pathway have
been shown to shape the gene expression pattern and
thus the cellular response in normal and transformed
epithelial cells [43]. Of note, Western blot analysis of
MDA-MB-231
EpCAM cells showed reduced levels of both
short and long TCF7L2 variants.
The role of ITF-2, which is strongly down-regulated in
MDA-MB-231
EpCAM cells, remains unclear. ITF-2 is a
basic-helix-loop-helix (bHLH) transcription factor. Its
interaction with the inhibitors of DNA binding Id-1 and
Id-2 proteins has been described. In complex with Id pro-
teins, ITF-2 can modulate the mammary epithelial cell
phenotype and malignant transformation [44]. Zhai et al
showed an interference between ITF-2 and Wnt signaling
[45]. Furthermore, the appearance of two isoformal var-
iants, ITF-2A and ITF-2B, differing substantially in
domain architecture and function, has been reported [30].
Finally, an increase in invasion and migration after
EpCAM overexpression was not observed. Such complex
processes are governed by multiple molecular changes.
The addition of a single gene might not be sufficient and
essential interaction partners might be absent in our ana-
lysed cell lines. As such, EpCAM has been described to
be a transcriptional target of p53 [46]. A loss of wild-type
p53 during breast cancer progression does probably not
result in a sole increase of EpCAM expression but also in
the regulation of other important target genes.
Conclusions
The effects of constitutive expression of the EpCAM
oncogene are dependent on the properties of parental
cell lines. Further, the functional alterations observed
in vitro were marginal, potentially due to the lack of
accessory molecules which might be necessary for
EpCAM to exert its full oncogenic potential. In MDA-
MB-231
EpCAM cells a nuclear accumulation of ß-
catenin and a significant upregulation of Wnt reporter
a s s a ya c t i v i t yw e r eo b s e r v e d .I nH s 5 7 8 T
EpCAM cells,
overexpression was accompanied by a considerable
decreased expression of the Wnt pathway inhibitor
SFRP1, by an increased proliferation rate and enhanced
sensitivity to Docetaxel. Certainly, future investigations
are warranted to define the functional relationship
between increase of EpCAM expression, Wnt signaling
and oncogenic features.
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